Multitarget designs and microenvironment remodeling may overcome resistance to CAR T-cell therapy in B-cell malignancies
New Strategies Identified to Overcome CAR T-cell Therapy Resistance
This systematic review synthesizes current knowledge regarding resistance mechanisms and overcoming strategies for CAR T-cell therapy in rel…
Researchers identified specific ways to overcome resistance in CAR T-cell therapy for patients with certain types of blood cancers.
Meta-analysis of novel therapies for follicular lymphoma progression within 24 months shows high response rates
New treatments show high response rates for advanced follicular lymphoma patients
This systematic review and meta-analysis evaluated outcomes for patients with follicular lymphoma experiencing disease progression within 24…
New powerful medicines help 91% of advanced follicular lymphoma patients whose disease returned quickly after treatment.
CAR T-cell therapy linked to endocrine adverse events in FAERS analysis
CAR T-cell therapy may trigger rare but serious hormone problems like adrenal failure
A retrospective disproportionality analysis and literature review of 269 endocrine adverse event reports from the FAERS database (2017 to Q2…
CAR T-cell therapy can trigger rare but serious hormone problems like adrenal failure, and death risk rises when these issues occur with sev…
BCMA CAR-T therapy achieves 100% MRD negativity in transplant-ineligible multiple myeloma patients
A One-Time Treatment Erases Early-Stage Blood Cancer in Older Adults
This Phase II, open-label, single-arm trial evaluated BCMA CAR-T infusion in 36 patients with newly diagnosed multiple myeloma ineligible fo…
A new approach using a patient’s own re-engineered immune cells is showing unprecedented success in wiping out a common blood cancer from th…